Acute liver injury associated with tirzepatide: an unexpected adverse event warranting clinical attention.

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type-2 diabetes and for weight management. While generally well-tolerated, common advers…

Preview only. Read the full abstract at the source